Skip to main
RAPP
RAPP logo

RAPP Stock Forecast & Price Target

RAPP Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rapport Therapeutics Inc has seen a significant increase in momentum following its inaugural R&D Day and the positive Phase 2a data released on September 8, indicating strong investor interest and confidence in the company's direction. The company's RAP-219 has demonstrated a significantly improved therapeutic window in a first-in-patient pilot study involving 30 patients with refractory focal onset epilepsy, strengthening its clinical viability. Additionally, supportive preclinical and Phase 1 human volunteer studies suggest that even a modest reduction in efficacy could still result in successful outcomes in future Phase 3 trials, potentially positioning the drug with a commercially competitive profile.

Bears say

Rapport Therapeutics Inc. faces significant challenges as its Phase 2a efficacy data, which may be overstated due to missing patient data, raises concerns about the potential effectiveness in future Phase 3 trials. The company operates in a competitive market, where even successful regulatory approvals may not guarantee a favorable commercial outcome due to the threat of competition and potential unfavorable insurance coverage. Furthermore, while there is a high unmet need in treating life-threatening seizures, these factors collectively contribute to a negative outlook on the company's stock performance.

RAPP has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rapport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rapport Therapeutics Inc (RAPP) Forecast

Analysts have given RAPP a Strong Buy based on their latest research and market trends.

According to 4 analysts, RAPP has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rapport Therapeutics Inc (RAPP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.